搜索优化
Rewards
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
过去 7 天
时间不限
过去 1 小时
过去 24 小时
过去 30 天
按相关度排序
按时间排序
3 小时
This Stock Is Crushing Nvidia's Performance This Year: Is It Too Late to Buy?
Few companies have attracted more attention this year than Nvidia. The chipmaker is on a roll thanks to the rapid rise of ...
6 天
Promising Anti-Tumor Activity and Safety of Ivonescimab in Combination Therapies in CRC ...
Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that data for the novel, potential ...
3 天
Summit Therapeutics Bests Merck's Top Selling Drug In Phase III Trial
Summit Therapeutics' ivonescimab poised for FDA approval, with the potential to disrupt the oncology market. Read more on ...
6 天
on MSN
Akeso’s Ivonescimab plus Chemo in First-Line Triple-negative Breast Cancer Showed ...
At the 2024 European Society for Medical Oncology (ESMO) Conference, Akeso (9926.HK) published the phase 2 results from its ...
clinicaltrialsarena
2 天
Keytruda beaten by Summit’s bispecific in NSCLC
Summit Therapeutics and Akeso published results for the Phase III HARMONi-2 trial, which tested ivonescimab, a bispecific ...
4 天
This Company Generates No Revenue and Its Market Cap Is Over $20 Billion. Here's Why That ...
If a company shows a lot of potential, investors are often willing to pay a premium and take on some risk in exchange for ...
2 天
Iranian Immigrant Becomes Billionaire As Her Biotech Firm’s Stock Soars
Shares of Summit Therapeutics, whose cancer drug candidate turned heads after it outperformed a blockbuster drug from Merck, ...
ThePrint
2 天
This experimental lung cancer drug outperforms blockbuster medicine Keytruda. But there’s ...
In head-to-head clinical trial, Chinese firm Akeso’s ivonescimab beat top-selling drug pembrolizumab sold as Keytruda by Merck. Ivonescimab reduced risk of tumour progression by 49%.
BioSpace
4 天
Despite Win Over Keytruda, Summit’s NSCLC Bispecific Still Has Something to Prove
Summit Therapeutics’ ivonescimab has the potential to challenge Merck’s blockbuster checkpoint inhibitor in non-small cell ...
5 天
Here's Why Everyone's Talking About Summit Therapeutics
Summit Therapeutics acquired rights to ivonescimab outside of China and Australia. With Keytruda sales up around $25 billion ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈